Physical exercise recommendations for patients with chronic myeloid leukemia based on individual preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)
- PMID: 38450192
- PMCID: PMC10915004
- DOI: 10.3389/fonc.2024.1345050
Physical exercise recommendations for patients with chronic myeloid leukemia based on individual preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)
Abstract
Background: Tyrosine kinase inhibitors (TKIs) have significantly lowered mortality of chronic myeloid leukemia (CML) patients adjusting life expectancy to that of the standard population. However, CML and its treatment with TKIs causes a high disease burden. Physical exercise (PE) could be a non-pharmacological approach to reducing these and improving quality of life.
Purpose: The aim of this study was to determine the individual disease burden as well as PE preferences of CML patients and to deduce thereof specific PE recommendations.
Methods: This multicenter survey was conducted in cooperation with the LeukaNET/Leukemia-patient network including CML patients aged ≥18 years (German Registry of Clinical Trials, DRKS00023698). The severity of selected symptoms was assessed using the adapted Myeloproliferative Neoplasms Symptom Assessment Form: 0 (absent), 1-30 (mild), 31-70 (moderate), or 71-100 (severe). Information about patients' PE needs and preferences depending on their motivation was recorded.
Results: A total of 212 questionnaires were analyzed (52% female, median age 54 years). The prevalence of moderate-to-severe symptoms was 49% for fatigue, 40% for musculoskeletal pain, and 37% for concentration problems. Other commonly reported symptoms included skin reactions (42%) and weight gain (24%). The proportion of overweight/obese patients was 52%. Half of all respondents requested more information regarding PE. Patients with CML preferred individual training (82%), located outdoors (71%), at home (47%), or in an indoor swimming pool (31%). Regarding the training frequency, sports-inactive patients preferred a frequency of 1-2 training sessions per week, whereas sports-active patients preferred 3-4 sessions per week (p <0.001). Sports-inactive patients preferred a training time of 15-45 minutes, while sports-active patients preferred 30-60 minutes (p = 0.002). Subsequently, PE recommendations were developed for patients with CML. Combined resistance and endurance training (moderate intensity twice per week for 30 minutes) was recommended for beginners. Obese patients should prioritize joint-relieving sports. To reduce the risk of skin reactions, direct sunlight and possibly water sports should be avoided, and UV protection should be used.
Conclusion: Counseling and motivation of CML patients to be physically active should be part of the standard of care as well as support for implementation.
Keywords: chronic myeloid leukemia (CML); health-related quality of life (QOL); myeloproliferative neoplasm (MPN); physical activity; physical exercise recommendation.
Copyright © 2024 Hollenbach, Rogahn, le Coutre, Schulze, Muegge, Geissler, Gruen, Junghanss and Felser.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Figures
Similar articles
-
Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97).Cancer Med. 2023 Sep;12(17):18235-18245. doi: 10.1002/cam4.6413. Epub 2023 Aug 9. Cancer Med. 2023. PMID: 37559463 Free PMC article.
-
Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97).Front Oncol. 2023 Jan 4;12:1056786. doi: 10.3389/fonc.2022.1056786. eCollection 2022. Front Oncol. 2023. PMID: 36686756 Free PMC article.
-
Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.Clin Lymphoma Myeloma Leuk. 2020 Dec;20(12):836-842. doi: 10.1016/j.clml.2020.08.009. Epub 2020 Aug 18. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32958432
-
Current perspectives for the treatment of chronic myeloid leukemia.Turk J Med Sci. 2019 Feb 11;49(1):1-10. doi: 10.3906/sag-1810-81. Turk J Med Sci. 2019. PMID: 30761815 Free PMC article. Review.
-
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.Blood Rev. 2021 Sep;49:100825. doi: 10.1016/j.blre.2021.100825. Epub 2021 Mar 16. Blood Rev. 2021. PMID: 33773846 Free PMC article. Review.
References
-
- Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, et al. . Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. (2017) 31):2398–406. doi: 10.1038/leu.2017.253 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources